Tampere Coronary Artery Disease and Sudden Cardiac Arrest Study
Key facts
- Where
- Tampere, FinlandSee the site
Where in Finland
- Tampere University Hospital Tampere Heart CentreTampere, FinlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tampere Heart Hospital
- Trial code
- NCT06804499
- Record updated
- 25 August 2026
- Original description
The goal of this observational study is to recognize clinical and genetic risk factors for sudden cardiac arrest (SCA) and death (SCD) in patients with coronary artery disease (CAD).Read full original descriptionShow less
The goal of this observational study is to recognize clinical and genetic risk factors for sudden cardiac arrest (SCA) and death (SCD) in patients with coronary artery disease (CAD).
The main questions it aims to answer are:
Are we able to recognize clinical or treatment-related risk factors for SCA or SCD? Can we identify new genetic risk factors for SCA or SCD in patients under 75 years?
Participants diagnosed with CAD answer a short survey about their medical history and socioeconomic status. A standard ECG addition to a five (5) minute ECG recording is taken from all the study subjects. In addition to a few short physiological tests (e.g. blood pressure, height, weight, grip strength), a blood sample is withdrawn from a selected group of study subjects.
Medical healthcare records are used to follow all study subjects, and no follow-up visits are required.
Inclusion: Age > 18 years; A patient who lives in the area of 'Wellbeing Services County of Pirkanmaa' and seeks treatment for coronary artery disease (CAD); CAD is diagnosed with invasive coronary angiogram or computed tomography angiogram (CTA) which is evaluated by cardiologists based on current guidelines for stenosis level evaluation and fractional flow reserve (FFR) results; An invasive coronary angiogram or CTA is done within three (3) months; Good or moderate everyday functional ability.
Exclusion: A significant valvular heart disease treated previously (endovascular or surgical) or requires treatment (endovascular or surgical) in the next three (3) months; Previously implanted cardioverter-defibrillators (ICD) or will be implanted in the next three (3) months; An active malignancy (ongoing treatment for a solid tumour, metastatic solid tumour, fast progressing haematological malignancy, or equal malignant disease); A significant neurodegenerative disease (dementia, Mini-Mental State Examination (MMSE) <23 or equivalenneurodegenerative disease affecting everyday functional ability, like ALS, myositis, prograded MS-disease or Parkinson's disease); Do-not-resuscitate (DNR) treatment decision; Subgroup with blood samples:; Blood samples are withdrawn from all study subjects under 76 years of age. Additionally, PaxGene samples are withdrawn from i) all study subjects under 65 years of age and ii) subjects between 65-76 years, if they have detected QRS-time>110ms in the latest ECG; Life expectancy <1 months; Intellectual disability or a significant disability affecting cognitive functions.